Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS) (ALSTAR OL)
A Multinational, Multicenter, Open Label Phase to Assess Tolerability and Safety of Talampanel 50mg Tid in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Terminated
Core study unsuccessful
Other terminated trials from Teva Branded Pharmaceutical Products R&D, Inc.
- Multiple Myeloma · Phase PHASE1/PHASE2 · Nov 2024
- Multiple Myeloma · Phase PHASE1 · Jun 2024
- Multiple Myeloma · Phase PHASE1/PHASE2 · May 2024
- Melanoma · Phase PHASE1/PHASE2 · Dec 2023
- Cerebral Palsy, Dyskinetic · Phase PHASE3 · Feb 2023
More terminations from Teva Branded Pharmaceutical Products R&D, Inc.
Other Amyotrophic Lateral Sclerosis trials with similar outcome
A PHASE2 clinical study on Amyotrophic Lateral Sclerosis, this trial is terminated or withdrawn. The trial is conducted by Teva Branded Pharmaceutical Products R&D, Inc. and has accumulated 8 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2022 — Apr 2022 [monthly]
Terminated PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Sep 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Teva Branded Pharmaceutical Products R&D, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.